SunBio,Inc. (067370.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩5,620 (-0.18%) as of
Key statistics
- Market cap
- 68.48B
- Dividend yield
- 0.00%
- 52-week range
- 0.00 – 8,500.00
- Beta
- 0.65
- Revenue (TTM)
- 2.17B
- Profit margin
- 64.22%
About SunBio,Inc.
SunBio,Inc., a biotech company, develops, produces, and sells biosimilar and biopharmaceutical products, and medical devices based on its technologies of pegylation worldwide. Its biosimilar products include PEG-filgrastim; and PEG-EPO and uricase which is in preclinical stage. The company offers MucoPEG, a medical device for treatment of dry mouth syndrome; and SynoGEL, a viscosupplement for arthritic Knee. Its preclinical stage biopharmaceuticals candidates target brain stroke and chronic anemia. It also manufactures and sells PEG derivatives. The company was founded in 1997 and is headquartered in Gunpo-si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Gunpo-si, South Korea
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.